NUP98 and leukemia: Additionally, administration of VTP50469 resulted in improved survival outcomes in mice with NUP98-rearranged leukemias 29, highlighting the potential of VTP50469 as a targeted agent for the treatment of patients with NUP98-rearranged leukemias.